Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck
Autor: | Daniela Heine, Moritz F. Meyer, Johannes A. Veit, Sacha Gnjatic, Inga Grünewald, Patrick J. Schuler, Dirk Beutner, Jochen K. Lennerz, Gerd Ritter, Thomas K. Hoffmann, Julia Thierauf, Theresa L. Whiteside, Andrew G. Sikora, Simon Laban, Subasch Shetty |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Adenoid cystic carcinoma business.industry Head and neck cancer medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Otorhinolaryngology Antigen 030220 oncology & carcinogenesis Internal medicine medicine Cancer/testis antigens Immunohistochemistry Clinical significance NY-ESO-1 business Survival analysis |
Zdroj: | Head & Neck. 38:1008-1016 |
ISSN: | 1043-3074 |
Popis: | Background Adenoid cystic carcinoma (ACC) of the head and neck is a rare but highly malignant tumor. Cancer-testis antigens (CTAs) represent an immunogenic family of cancer-specific proteins and thus represent an attractive target for immunotherapy. Methods Eighty-four cases of ACC were identified, the CTAs pan-Melanoma antigen (pan-MAGE; M3H67) and New York esophageal squamous cell carcinoma (NY-ESO-1; E978) were detected immunohistochemically (IHC) and correlated with clinical data. Results Expression of NY-ESO-1 was found in 48 of 84 patients (57.1%) and of pan-MAGE in 28 of 84 patients (31.2%). Median overall survival (OS) in NY-ESO-1 positive versus negative patients was 130.8 and 282.0 months (p = .223), respectively. OS in pan-MAGE positive versus negative patients was 105.3 and 190.5 months, respectively (p = .096). Patients expressing both NY-ESO-1 and pan-MAGE simultaneously had significantly reduced OS with a median of 90.5 months compared with 282.0 months in negative patients (p = .047). Conclusion A significant fraction of patients with ACC show expression of the CTAs NY-ESO-1 and/or pan-MAGE with promising immunotherapeutic implications. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1008–1016, 2016 |
Databáze: | OpenAIRE |
Externí odkaz: |